KLKelly Lindert

Kelly Lindert

*This is an algorithmically generated author record based on publicly available information.

Kelly Lindert has a total of 42 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Phase 3 Randomized Study Investigating the Safety, Tolerability, and Immunogenicity of a Combination Modified Messenger RNA Vaccine Against Influenza and COVID-19 in Healthy Adults

    by Yanely Pineiro Puebla, Helen Nicholls, David Fitz-Patrick, Lucy E. Horton, Matthew W. Gawel, Reynold Duarte Martinez, Xingbin Wang, Georgina Keep, Xia Xu, Emily Gomme, et al.

    Background/Objectives: Vaccination remains an important means of protection against influenza and COVID-19. Administering influenza and COVID-19 vaccines as a combined formulation may be advantageous. Methods: This phase 3, randomized study evaluated an investigational combination nucleoside-modified messenger RNA (modRNA) vaccine formulated with monovalent XBB.1.5-adapted BNT162b2 vaccine (BNT162b2) and an investigational influenza modRNA vaccine (hereafter investigational combination modRNA vaccine); we report safety, tolerability, and immunogenicity of the investigational combination modRNA vaccine in healthy 18- to 64-year-olds in two cohorts (2 and 3). Results: In Cohort 2, 3127 participants received the investigational combination modRNA vaccine and 1563 received the concomitant licensed quadrivalent influenza vaccine (QIV) with BNT162b2. In Cohort 3, 1189 participants received the investigational combination modRNA vaccine, 605 received QIV, 607 received the investigational influenza modRNA vaccine, and 1191 received BNT162b2. Prespecified noninferiority criteria of the geometric mean ratio of strain-specific hemagglutination inhibition (HAI) or SARS-CoV-2 Omicron XBB.1.5 neutralizing titers or differences in percentages of participants achieving HAI sero-conversion or Omicron XBB.1.5 seroresponse for investigational combination modRNA vaccine to concomitant QIV and BNT162b2 (or to QIV and BNT162b2 each administered alone in Cohort 3) were met for influenza A and SARS-CoV-2 Omicron XBB.1.5 strains but not for the influenza B strain. The investigational combination modRNA vaccine was well tolerated with an acceptable safety profile. Conclusions: The single-dose investigational combination influenza plus COVID-19 modRNA vaccine elicited robust immune responses against influenza A and SARS-CoV-2 with acceptable safety. Further work is required to optimize influenza B responses. The modRNA platform offers promise and potential advantages for vaccine development. ClinicalTrials.gov Identifier: NCT06178991 (approval date: 20 December 2023).


  • Open Access

    A Study to Investigate the Safety and Immunogenicity of Monovalent Omicron LP.8.1-Adapted BNT162b2 COVID-19 Vaccine in Adults ≥ 65 Years of Age and High-Risk Adults 18–64 Years of Age (Preliminary Results)

    by Rucha Dadhe, Juleen Gayed, Muneeb Iqbal, Rohit Solan, Han Wu, Hua Ma, Xia Xu, Federico J. Mensa, Todd Belanger, David Cooper, et al.

    Background/Objectives: This study evaluated the Omicron LP.8.1 variant-adapted BNT162b2 mRNA vaccine (LP.8.1-adapted BNT162b2). Methods: This analysis is part of an ongoing phase 3 open-label study evaluating the immunogenicity, safety, and tolerability of LP.8.1-adapted BNT162b2. Reported here are descriptive 2-week post-vaccination results in 18–64 -year-olds at high risk of severe COVID-19 and in ≥65-year-olds who received the Omicron KP.2-adapted COVID-19 vaccine ≥ 6 months previously. Primary immunogenicity endpoints included neutralizing antibody geometric mean titers (GMTs) against LP.8.1 and KP.2 at 2 weeks after vaccination and geometric mean fold rises from baseline to 2 weeks after vaccination. Results were compared with a historical control group of adults who received KP.2-adapted BNT162b2 in a previous study. Tolerability and safety were also assessed. Results: Overall, 104 participants received LP.8.1-adapted BNT162b2 (18–64-year-olds, n = 51; ≥65-year-olds, n = 53). Baseline neutralizing GMTs were higher in LP.8.1-adapted BNT162b2 recipients than in the historical control group of KP.2-adapted BNT162b2 recipients against both sublineages (248 vs. 157 against LP.8.1; 372 vs. 187 against KP.2). Serum-neutralizing LP.8.1 and KP.2 GMTs increased 2 weeks after vaccination with LP.8.1-adapted BNT162b2 (1752 against LP.8.1; 2104 against KP.2) and historical control groups (1555 and 2395, respectively), and across both age groups. Reactogenicity events with LP.8.1-adapted BNT162b2 were generally mild or moderate and occurred at generally similar frequencies in both age groups. Adverse events were reported in 4.8% of participants (all in 18–64-year-olds); no serious adverse events were reported. Conclusions: After 2 weeks of follow-up, and in a small sample size, LP.8.1-adapted BNT162b2 was immunogenic in ≥65-year-olds and ≥18-year-olds at high risk of severe COVID-19. The safety and tolerability profile for LP.8.1-adapted BNT162b2 was consistent with the current US prescribing information for BNT162b2 and that of other variant-adapted BNT162b2 vaccines (Clinicaltrials.gov Identifier: NCT07069309, registered 16 July 2025).


  • Open Access

    A Phase 1/2 Randomized Study to Evaluate the Safety, Tolerability, and Immunogenicity of Nucleoside-Modified Messenger RNA Influenza Vaccines in Healthy Adults

    by Angela Branche, Mark J. Mulligan, Alok Maniar, Orlando Puente, Islamiat Oladipupo, Graham Crowther, Agnieszka M. Zareba, Zhuobiao Yi, Ingrid Scully, Emily Gomme, et al.

    Background/Objectives: Circulating influenza strains antigenically differing from vaccine antigens increase disease burden by decreasing vaccine efficacy. Nucleoside-modified mRNA (modRNA) influenza vaccines may facilitate rapid production allowing later antigen selection and improved antigenic similarity compared to circulating strains. We studied different influenza modRNA vaccine (IRV) formulations and dose levels. Methods: This phase 1/2 randomized study evaluated IRV safety/tolerability and immunogenicity in healthy 18- through 85-year-olds. Based on safety and immunogenicity for different IRV doses, schedules, and valencies versus the quadrivalent influenza vaccine (QIV; Fluzone High-Dose Quadrivalent, Sanofi Pasteur) in phase 1 (65–85-year-olds), quadrivalent IRV (qIRV) was further evaluated in 65- through 85-year-olds and 18- through 64-year-olds in phase 2, leading to phase 3 dose selection. Results: Phase 1 (65–85-year-olds) safety/tolerability and immunogenicity findings supported qIRV 30-µg and 60-µg phase 2 assessment (18–85-year-olds, N = 610). qIRV was well tolerated. Injection site pain was the most frequently reported local reaction. Reactogenicity event incidences ≤ 7 days postvaccination for qIRV were generally higher versus QIV, observed more frequently in 18- through 64-year-olds than 65- through 85-year-olds, and showed dose-related trends (60 μg > 30 μg). qIRV and QIV adverse event profiles in 65- through 85-year-olds were similar. There were higher postvaccination hemagglutination inhibition assay geometric mean titers and fold rises and seroconversion rates observed with qIRV versus QIV for A strains, with no consistent pattern for B strains. Cell-mediated immune responses to qIRV by Day 7 showed overall higher T-cell responses against all strains versus QIV. Antibody and cell-mediated immune responses showed comparable trends across qIRV doses in 18- through 85-year-olds; a dose-related pattern was observed in 65- through 85-year-olds (60 μg > 30 μg). Conclusions: Phase 3 investigations of qIRV 60 µg in older adults and qIRV 30 µg in younger adults are warranted (ClinicalTrials.gov Identifier: NCT05052697).